Irritable bowel syndrome symptom severity improves equally with probiotic and placebo

World Journal of Gastroenterology

Volumn 22, Issue 48, 2016, Pages 10631-10642

  Lyra, Anna ^a   Hillilä, Markku ^b   Huttunen, Teppo ^c   Männikkö, Sofia ^c   Taalikka, Mikko ^c   Tennilä, Julia ^a   Tarpila, Anneli ^a   Lahtinen, Sampo ^a   Ouwehand, Arthur C ^a   Veijola, Lea ^d  

^a Danisco Finland Oy   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c 4Pharma Ltd   (Finland)

^d Mehilainen Oy   (Finland)

Author keywords

Abdominal pain; Functional bowel disorder; Intervention; Irritable bowel syndrome; Lactobacillus acidophilus; Probiotic; Quality of life; Symptom questionnaire; Visceral pain

Indexed keywords

PLACEBO; PROBIOTIC AGENT; OPIATE RECEPTOR;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ANXIETY; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEFECATION; DEPRESSION; DIARRHEA; DISABILITY SEVERITY; DISEASE SEVERITY ASSESSMENT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FAINTNESS; FECES; FEMALE; FLATULENCE; GASTROENTERITIS; HUMAN; IBS SYMPTOM SEVERITY SCORE; INFLUENZA; IRRITABLE COLON; LACTOBACILLUS ACIDOPHILUS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PNEUMONIA; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; CHEMISTRY; CLINICAL TRIAL; COLON; DOSE RESPONSE; DRUG EFFECTS; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PAIN MEASUREMENT; PHASE 2 CLINICAL TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VISCERAL PAIN;

ABDOMINAL PAIN; ADULT; COLON; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; LACTOBACILLUS ACIDOPHILUS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PROBIOTICS; RECEPTORS, OPIOID; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; VISCERAL PAIN;

EID: 85008233310     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i48.10631     Document Type: Article

References (33)

1. Hillilä MT, Färkkilä MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment Pharmacol Ther 2004; 20: 339-345 [PMID: 15274671 DOI: 10.1111/j.1365-2036.2004.02034.x]
2. Krogsgaard LR, Engsbro AL, Bytzer P. The epidemiology of irritable bowel syndrome in Denmark. A population-based survey in adults 50 years of age. Scand J Gastroenterol 2013; 48: 523-529 [PMID: 23506174 DOI: 10.3109/00365521.2013.775328]
3. EFSA. Guidance on the scientific requirements for health claims related to gut and immune function. EFSA 2011; 9: 1984 [DOI: 10.2903/j.efsa.2011.1984]
4. Hyland NP, Quigley EM, Brint E. Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions. World J Gastroenterol 2014; 20: 8859-8866 [PMID: 25083059 DOI: 10.3748/wjg.v20.i27.8859]
5. Kennedy PJ, Cryan JF, Dinan TG, Clarke G. Irritable bowel syndrome: a microbiome-gut-brain axis disorder World J Gastroenterol 2014; 20: 14105-14125 [PMID: 25339800 DOI: 10.3748/wjg.v20.i39.14105]
6. Rajili-Stojanovi M, Jonkers DM, Salonen A, Hanevik K, Raes J, Jalanka J, de Vos WM, Manichanh C, Golic N, Enck P, Philippou E, Iraqi FA, Clarke G, Spiller RC, Penders J. Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena Am J Gastroenterol 2015; 110: 278-287 [PMID: 25623659 DOI: 10.1038/ajg.2014.427]
7. Moloney RD, Johnson AC, O'Mahony SM, Dinan TG, Greenwood-Van Meerveld B, Cryan JF. Stress and the Microbiota-Gut-Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome. CNS Neurosci Ther 2016; 22: 102-117 [PMID: 26662472 DOI: 10.1111/cns.12490]
8. Bonfrate L, Tack J, Grattagliano I, Cuomo R, Portincasa P. Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options. Scand J Gastroenterol 2013; 48: 995-1009 [PMID: 23964766 DOI: 10.310 9/00365521.2013.799220]
9. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11: 506-514 [PMID: 24912386 DOI: 10.1038/nrgastro.2014.66]
10. Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Moayyedi P. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 1547-1561; quiz 1546, 1562 [PMID: 25070051 DOI: 10.1038/ajg.2014.202]
11. Hungin AP, Mulligan C, Pot B, Whorwell P, Agréus L, Fracasso P, Lionis C, Mendive J, Philippart de Foy JM, Rubin G, Winchester C, de Wit N. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice-an evidencebased international guide. Aliment Pharmacol Ther 2013; 38: 864-886 [PMID: 23981066 DOI: 10.1111/apt.12460]
12. Wall GC, Bryant GA, Bottenberg MM, Maki ED, Miesner AR. Irritable bowel syndrome: a concise review of current treatment concepts. World J Gastroenterol 2014; 20: 8796-8806 [PMID: 25083054 DOI: 10.3748/wjg.v20.i27.8796]
13. Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EM, Sartor RB, Sherman PM, Mayer EA. An update on the use and investigation of probiotics in health and disease. Gut 2013; 62: 787-796 [PMID: 23474420 DOI: 10.1136/gutjnl-2012-302504]
14. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, Dubuquoy C, Merour E, Geboes K, Chamaillard M, Ouwehand A, Leyer G, Carcano D, Colombel JF, Ardid D, Desreumaux P. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007; 13: 35-37 [PMID: 17159985 DOI: 10.1038/nm1521]
15. Ringel-Kulka T, Goldsmith JR, Carroll IM, Barros SP, Palsson O, Jobin C, Ringel Y. Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain-a randomised clinical study. Aliment Pharmacol Ther 2014; 40: 200-207 [PMID: 24853043 DOI: 10.1111/ apt.12800]
16. Ringel-Kulka T, Palsson OS, Maier D, Carroll I, Galanko JA, Leyer G, Ringel Y. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J Clin Gastroenterol 2011; 45: 518-525 [PMID: 21436726 DOI: 10.1097/MCG.0b013e31820ca4d6]
17. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491 [PMID: 16678561 DOI: 10.1053/j.gastro. 2005.11.061]
18. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997; 11: 395-402 [PMID: 9146781 DOI: 10.1046/j.1365-2036.1997.142318 000.x]
19. Simrén M, Ohman L, Olsson J, Svensson U, Ohlson K, Posserud I, Strid H. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome-a randomized, double-blind, controlled study. Aliment Pharmacol Ther 2010; 31: 218-227 [PMID: 19863495 DOI: 10.1111/ j.1365-2036.2009.04183.x.]
20. Williams EA, Stimpson J, Wang D, Plummer S, Garaiova I, Barker ME, Corfe BM. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 2009; 29: 97-103 [PMID: 18785988 DOI: 10.1111/j.1365-2036.2008.03848.x.]
21. Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998; 43: 400-411 [PMID: 9512138]
22. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370 [PMID: 6880820 DOI: 10.1111/j.1600-0447.1983.tb09716.x]
23. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32: 920-924 [PMID: 9299672 DOI: 10.3109/00365529709011203]
24. Passos MC, Lembo AJ, Conboy LA, Kaptchuk TJ, Kelly JM, Quilty MT, Kerr CE, Jacobson EE, Hu R, Friedlander E, Drossman DA. Adequate relief in a treatment trial with IBS patients: a prospective assessment. Am J Gastroenterol 2009; 104: 912-919 [PMID: 19293784 DOI: 10.1038/ajg.2009.13]
25. Urbaniak G, Plous S. Research Randomizer. 4.0 ed, 2012: Computer software. Available at: URL: https://www.randomizer. org/
26. Altermann E, Russell WM, Azcarate-Peril MA, Barrangou R, Buck BL, McAuliffe O, Souther N, Dobson A, Duong T, Callanan M, Lick S, Hamrick A, Cano R, Klaenhammer TR. Complete genome sequence of the probiotic lactic acid bacterium Lactobacillus acidophilus NCFM. Proc Natl Acad Sci USA 2005; 102: 3906-3912 [PMID: 15671160 DOI: 10.1073/ pnas.0409188102]
27. D'Souza B, Slack T, Wong SW, Lam F, Muhlmann M, Koestenbauer J, Dark J, Newstead G. Randomized controlled trial of probiotics after colonoscopy. ANZ J Surg 2015; Epub ahead of print [PMID: 26183594 DOI: 10.1111/ans.13225]
28. Childs CE, Röytiö H, Alhoniemi E, Fekete AA, Forssten SD, Hudjec N, Lim YN, Steger CJ, Yaqoob P, Tuohy KM, Rastall RA, Ouwehand AC, Gibson GR. Xylo-oligosaccharides alone or in synbiotic combination with Bifidobacterium animalis subsp. lactis induce bifidogenesis and modulate markers of immune function in healthy adults: a double-blind, placebo-controlled, randomised, factorial cross-over study. Br J Nutr 2014; 111: 1945-1956 [PMID: 24661576 DOI: 10.1017/S0007114513004261]
29. Jeffery IB, O'Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EM, Simrén M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61: 997-1006 [PMID: 22180058 DOI: 10.1136/gutjnl-2011-301501]
30. Engsbro AL, Simren M, Bytzer P. Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification. Aliment Pharmacol Ther 2012; 35: 350-359 [PMID: 22176384 DOI: 10.1111/j.1365-2036.2011.04948.x]
31. Sisson G, Ayis S, Sherwood RA, Bjarnason I. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome-a 12 week double-blind study. Aliment Pharmacol Ther 2014; 40: 51-62 [PMID: 24815298 DOI: 10.1111/ apt.12787]
32. Lackner JM, Jaccard J, Keefer L, Firth R, Carosella AM, Sitrin M, Brenner D. The accuracy of patient-reported measures for GI symptoms: a comparison of real time and retrospective reports. Neurogastroenterol Motil 2014; 26: 1802-1811 [PMID: 25424582 DOI: 10.1111/nmo.12466]
33. Azpiroz F, Guyonnet D, Donazzolo Y, Gendre D, Tanguy J, Guarner F. Digestive Symptoms in Healthy People and Subjects With Irritable Bowel Syndrome: Validation of Symptom Frequency Questionnaire. J Clin Gastroenterol 2015; 49: e64-e70 [PMID: 25014236 DOI: 10.1097/MCG.0000000000000178]